APA (7th ed.) Citation

Schwarz, C., Sutharsan, S., Epaud, R., Klingsberg, R. C., Fischer, R., Rowe, S. M., . . . Bruinsma, B. G. (2021). Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events. Journal of Cystic Fibrosis, 20(2), 228. https://doi.org/10.1016/j.jcf.2020.06.001

Chicago Style (17th ed.) Citation

Schwarz, Carsten, et al. "Tezacaftor/ivacaftor in People with Cystic Fibrosis Who Stopped Lumacaftor/ivacaftor Due to Respiratory Adverse Events." Journal of Cystic Fibrosis 20, no. 2 (2021): 228. https://doi.org/10.1016/j.jcf.2020.06.001.

MLA (9th ed.) Citation

Schwarz, Carsten, et al. "Tezacaftor/ivacaftor in People with Cystic Fibrosis Who Stopped Lumacaftor/ivacaftor Due to Respiratory Adverse Events." Journal of Cystic Fibrosis, vol. 20, no. 2, 2021, p. 228, https://doi.org/10.1016/j.jcf.2020.06.001.